1015069-81-4

Basic information

• Product Name: tert-butyl 3-benzyl-2-oxopyrrolidine-1-carboxylate
• Synonyms: tert-butyl 3-benzyl-2-oxopyrrolidine-1-carboxylate
• CAS NO: 1015069-81-4
• Molecular Weight: 275.348
• Mol File: 1015069-81-4.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: tert-butyl 3-benzyl-2-oxopyrrolidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 3-benzyl-2-oxopyrrolidine-1-carboxylate(1015069-81-4)
• EPA Substance Registry System: tert-butyl 3-benzyl-2-oxopyrrolidine-1-carboxylate(1015069-81-4)

Safety Data

• Hazardous Substances Data: 1015069-81-4(Hazardous Substances Data)

Upstream product

• 81976-70-7 3-benzyl-2-pyrrolidinone 
• 100-39-0 benzyl bromide 
• 85909-08-6 tert-butyl 2-oxopyrrolidine-1-carboxylate 

Downstream Products

• 1015069-80-3 (tert-butoxy)-N-[4-hydroxy-3-benzylbutyl]carboxamide 
• 1232954-02-7 t-butyl 3-benzyl-2-oxo-3-(trifluoromethyl)pyrrolidine-1-carboxylate 
• 1598387-09-7 tert-butyl 3-benzyl-3-difluoro(trimethylsilyl)methyl-2-oxopyrrolidine-1-carboxylate 
• 1364569-38-9 tert-butyl 3-benzyl-3-(difluoromethyl)-2-oxopyrrolidine-1-carboxylate 
• 81976-70-7 3-benzyl-2-pyrrolidinone 

Relevant articles and documents

Synthesis of quaternary α-perfluoroalkyl lactams via electrophilic perfluoroalkylation

Efficient protocols enabling the rapid installation of trifluoromethyl, as well as further functionalized fluoroalkyl groups by an electrophilic perfluoroalkylation of lactam-derived ketene silyl amides (KSAs) using hypervalent iodine reagents 1 and 2 have been developed.

Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith

Provided herein are Heterocyclic Compounds having the following structure: wherein R1, R2, X, Y and Z are as defined herein, compositions comprising an effective amount of a Heterocyclic Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heterocyclic Compound to a patient in need thereof.